Recent news coverage includes general market and commodity updates unrelated to Entera Bio's business operations or developments.

• Recent news items primarily cover commodity prices, bond ETFs, and general investment topics without direct relevance to Entera Bio's business or clinical progress [N1][N2][N3][N4][N5][N6][N7][N8].

Entera Bio's proprietary N-Tab™ platform offers a novel approach to oral peptide delivery, potentially transforming treatment for osteoporosis and other conditions. Successful completion of Phase 3 trials for EB613 and regulatory approvals could enable commercialization and revenue generation. Collaborations, such as with OPKO for oral OXM, diversify the pipeline and development risk. The company's strong liquidity position as of late 2025 supports ongoing development activities. If clinical and regulatory milestones are met, Entera Bio could establish a differentiated position in the oral peptide therapeutics market.

Entera Bio faces significant risks including clinical trial failures, regulatory delays, and inability to secure necessary funding for Phase 3 studies. The company's operations are concentrated in Israel, exposing it to geopolitical risks and regulatory restrictions related to Israeli Innovation Authority grants, which may limit technology transfer and complicate change of control transactions. The company has a history of net losses and substantial accumulated deficit, raising concerns about its ability to continue as a going concern without additional capital. Market acceptance of oral peptide therapies remains uncertain, and competition from alternative treatments may limit commercial potential.

Entera Bio's moat is based on its proprietary N-Tab™ oral delivery platform for peptides, which addresses a significant unmet need for oral peptide therapies. The platform's intellectual property and know-how are supported by Israeli Innovation Authority grants, which impose transfer restrictions that may limit competition and technology transfer. The company's focus on oral delivery of peptides, a challenging area in biopharmaceuticals, provides a potential competitive advantage if clinical and regulatory milestones are achieved. However, the company has not yet commercialized any products, and its moat depends on successful clinical development, regulatory approval, and market acceptance.

• Geopolitical and Operational Risks: Operations and key personnel are primarily based in Israel, exposing the company to risks from ongoing regional conflicts, military service obligations of employees, and potential disruptions to business and capital raising.
• Funding and Liquidity Risks: The company has incurred significant losses and negative cash flows, with liquidity sufficient only through mid-2026 excluding Phase 3 initiation. Additional capital raising is required, which may not be available on favorable terms or at all.
• Clinical and Regulatory Risks: Clinical development is uncertain and expensive, with risks of delays, failures, or additional regulatory requirements that could increase costs and extend timelines.
• Intellectual Property and Grant Restrictions: Israeli Innovation Authority grants impose restrictions on transferring technology outside Israel and require approvals and royalties, potentially limiting strategic transactions and operational flexibility.
• Market and Commercialization Risks: No products have been approved or commercialized; market acceptance of oral peptide therapies is unproven, and competition may limit revenue potential.

• Entera Bio Ltd. is a clinical-stage biotechnology company developing oral peptide and protein replacement therapies using its proprietary N-Tab™ platform.
• The company commenced operations in 2010 and has a limited operating history with no approved products or commercial revenues to date.
• Entera Bio's lead clinical candidate is EB613 for osteoporosis; it has completed Phase 2 trials and is preparing for a Phase 3 program.
• The company also collaborates with OPKO on oral OXM (GLP1/Glucagon tablet) and is conducting Phase 1 studies for this candidate.
• Research and development expenses increased to $4.3 million for the nine months ended September 30, 2025, reflecting ongoing clinical development and regulatory activities.
• General and administrative expenses were $4.2 million for the nine months ended September 30, 2025, including personnel and legal/IP costs.
• As of December 31, 2025, Entera Bio had cash and cash equivalents of approximately $7.1 million and current assets of $15.3 million, with current liabilities of $2.2 million, resulting in a strong current ratio of 6.94 and cash ratio of 3.23.
• The company reported a net loss of $11.4 million for the fiscal year ended December 31, 2025, and an accumulated deficit exceeding $122 million as of September 30, 2025.
• Entera Bio's operations and key personnel are primarily based in Israel, with additional advisors in the US, UK, Asia, and Europe.
• The company is subject to Israeli Innovation Authority (IIA) grant restrictions, including limitations on transferring technology outside Israel and obligations to pay royalties.
• Geopolitical risks related to ongoing conflicts in the Middle East, including Israel-Hamas war and regional hostilities, may impact operations and capital raising.
• The company has raised approximately $111.4 million since inception through equity offerings, private placements, and grants.
• Liquidity is sufficient to fund operations through mid-2026 excluding the initiation of the EB613 Phase 3 study, which requires additional capital that may not be available on favorable terms.
• Entera Bio's business model is focused on advancing clinical development programs, regulatory submissions, and preparing for potential commercialization of oral peptide therapies.
• The company has not generated revenue from product sales and does not expect to until regulatory approvals are obtained.
• Research and development activities are the primary focus, with expenses expected to vary based on clinical trial progress and regulatory requirements.
• The company faces risks related to clinical development uncertainties, regulatory approvals, manufacturing, and the need for additional capital.
• Financial income is primarily from interest on bank deposits and currency exchange differences; the functional currency is the US dollar.
• The company has a small workforce of 22 employees, mostly based in Israel, supplemented by external advisors.
• Entera Bio's financial statements have been prepared on a going concern basis with substantial doubt noted by auditors due to ongoing losses and capital needs.